FDA Approves Asciminib, Drug With Novel Action in CML : vima

This first-in-class STAMP inhibitor is approved for use in patients with chronic myeloid leukemia who have developed resistance to tyrosine kinase inhibitors.

Related Keywords

New York , United States , Boston , Massachusetts , Philadelphia , Pennsylvania , American , Gabrielas Hobbs , Michaelj Mauro , Lee Greenberger , Leukemia Lymphoma Society , Cancer Center , Drug Administration , American Hematological Society , Novartis , Specifically Targeting , Lymphoma Society , Myeloproliferative Neoplasms Program , Memorial Sloan Kettering Cancer Center , Trial Data , Mass General Cancer Center , Chronic Myelogenous Leukemia , Hematology , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Biologic Therapy , Tyrosine Kinase Inhibitor , Rlotinib , Efitinib , Matinib , U11248 , Unitinib , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Ituximab , Rastuzumab , Antiretroviral Therapy , Antiretroviral Therapy Art ,